within Pharmacolibrary.Drugs.ATC.L;

model L01XX40
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0001933333333333333,
    adminDuration  = 600,
    adminMass      = 1.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.126,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.148,
    k12             = 12.1,
    k21             = 12.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX40</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Omacetaxine mepesuccinate (also known as homoharringtonine) is an alkaloid antineoplastic agent approved for the treatment of chronic myeloid leukemia (CML) in adults with resistance and/or intolerance to two or more tyrosine kinase inhibitors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with chronic or accelerated phase chronic myeloid leukemia receiving subcutaneous administration.</p><h4>References</h4><ol><li><p>Nijenhuis, CM, et al., &amp; Schellens, JH (2016). Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. <i>Investigational new drugs</i> 34(5) 565–574. DOI:<a href=\"https://doi.org/10.1007/s10637-016-0360-9\">10.1007/s10637-016-0360-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27221729/\">https://pubmed.ncbi.nlm.nih.gov/27221729</a></p></li><li><p>Damlaj, M, et al., &amp; Assouline, SE (2016). A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. <i>Expert opinion on drug safety</i> 15(9) 1279–1286. DOI:<a href=\"https://doi.org/10.1080/14740338.2016.1207760\">10.1080/14740338.2016.1207760</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27367461/\">https://pubmed.ncbi.nlm.nih.gov/27367461</a></p></li><li><p>Nijenhuis, CM, et al., &amp; Beijnen, AJ (2016). Metabolite profiling of . <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 46(12) 1122–1132. DOI:<a href=\"https://doi.org/10.3109/00498254.2016.1152418\">10.3109/00498254.2016.1152418</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26998885/\">https://pubmed.ncbi.nlm.nih.gov/26998885</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX40;
